Q2
2021 report

Progressing our pipeline

April—June

- Total revenue of SEK 3,211 M (3 070), 5 per cent growth and 14 per cent at CER
- EBITA[1] was SEK 922 M (1,018), with an EBITA margin[1] of 29 per cent (33)
- Earnings per share (EPS) before dilution of SEK 0.91 (0.96)
- Haematology sales were SEK 2,125 M (2,037), 12 per cent growth at CER
- Sales for Elocta® were SEK 1,005 M (1,040), 2 per cent growth at CER
- Sales for Alprolix® were SEK 438 M (363), 27 per cent growth at CER
- Doptelet® grew by 42 per cent at CER to SEK 230 M
- Immunology sales were SEK 752 M (714), Gamifant® grew by 46 per cent at CER to SEK 168 M (132)
- Cash flow from operating activities of SEK 1,393 M (1,942)

January—June

- Total revenue of SEK 6,872 M (7,709), -11 per cent and -2 per cent at CER
- EBITA[1] was SEK 2,406 M (3,191), with an EBITA margin[1] of 35 per cent (41)
- EPS before dilution of SEK 3.27 (4.98)
- Haematology sales were SEK 4,003 M (4,431), -3 per cent at CER
- Sales for Elocta were SEK 1,861 M (2,399), -18 per cent at CER
- Sales for Alprolix were SEK 851 M (851), 6 per cent growth at CER
- Doptelet grew by 88 per cent at CER to SEK 411 M
- Immunology sales were SEK 2,305 M (2,514), Gamifant grew by 47 per cent at CER to SEK 301 M (236)
- Cash flow from operating activities of SEK 3,092 (3,828)

Significant events after the reporting period

- In July, Kineret® was submitted to EMA with a proposed indication for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia who are at risk of developing severe respiratory failure

Outlook 2021—unchanged

- Revenue for the full-year 2021 is expected to be in the range of SEK 14,000-15,000 M
- EBITA margin is expected to be in the range of 30-35 per cent of revenue

Total revenue Q2, SEK M

3,211

Revenue growth at CER, Q2

14%

EBITA margin[1] Q2

29%

Financial summary

SEK M	Q2 2021	Q2 2020	Change	H1 2021	H1 2020	Change	Full-year 2020
Total revenue	3,211	3,070	5%	6,872	7,709	-11%	15,261
Gross profit	2,428	2,381	2%	5,363	5,979	-10%	12,036
Gross margin[1]	76%	78%		78%	78%		79%
EBITA[1]	922	1,018	-9%	2,406	3,191	-25%	6,700
EBITA adjusted[1,2]	922	1,018	-9%	2,406	3,191	-25%	6,301
EBITA margin[1]	29%	33%		35%	41%		44%
EBITA margin adjusted[1,2]	29%	33%		35%	41%		41%
Profit for the period	268	283	-5%	964	1,465	-34%	3,245
Earnings per share, before dilution, SEK	0.91	0.96	-5%	3.27	4.98	-34%	11.01
Earnings per share, before dilution, SEK adjusted[1,2,3]	0.91	0.96	-5%	3.27	4.98	-34%	9.66

[1]Alternative Performance Measures (APMs), see page 19 for further information.

[2] EBITA 2020 excluding non-recurring items; other operating income related to the reversal of the CVR liability of SEK 399 M.

[3]EPS full-year 2020 excluding the reversal of the CVR liability of SEK 399 M.

CEO statement

We ended the second quarter on a positive note and are back to double-digit growth. Our figures are still impacted by the COVID-19 pandemic and its related restrictions and lockdowns, but as restrictions have eased, we have started to see improved market conditions. The quarter closed with revenue of SEK 3,211 M with growth at CER of 14 per cent. EBITA was SEK 922 M, with a margin of 29 per cent.

As stated previously, 2021 is a year of investment in our pipeline: we continue to advance our R&D portfolio and explore new indications for our products.

During the quarter, we advanced key products in our R&D portfolio such as pegcetacoplan and efanesoctocog alfa, as well as anakinra (Kineret) for the treatment of hyperinflammation related to COVID-19. The SAVE-MORE trial showed strong results and in July we submitted anakinra for the treatment of COVID-19 pneumonia in Europe. In April, the first patient was dosed in the phase 3 paediatric trial of efanesoctocog alfa (BIVV001). I am confident that efanesoctocog alfa has the potential to significantly improve treatment for people with haemophilia A.

Together with Apellis, we reported positive top-line results from the phase 3 PRINCE study evaluating the efficacy and safety of pegcetacoplan in treatment-naïve adults with paroxysmal nocturnal haemoglobinuria (PNH). In May, pegcetacoplan was approved as EMPAVELI™ in the US for the treatment of adults with PNH. The marketing authorisation application for pegcetacoplan for PNH is currently under review by the European Medicines Agency (EMA).

We were happy to receive good news on nirsevimab, our collaboration with AstraZeneca, as the MELODY phase 3 trial met its primary endpoint, and the MEDLEY phase 2/3 trial showed positive topline results.

Within business area **Haematology**, Doptelet product sales grew by 167 per cent at CER. Elocta and Alprolix showed steady patient growth – up 3 per cent for Elocta and 16 per cent for Alprolix compared with the same period last year, and 1 per cent and 4 per cent compared with Q1 2021. Sales were impacted by decreased consumption as a consequence of lockdowns and reduced activity among patients, and by mandatory price reduction in Germany. However, the continued patient gain underscores the competitiveness of our products. Revenue for Haematology reached SEK 2,125 M (2,037) for the second quarter, with growth at CER of 12 per cent. As previously communicated, we foresee double-digit price erosion for Elocta for full-year 2021, driven primarily by mandated pricing changes.

Doptelet has shown progress since its US launch, with new prescribed patients as the main growth driver. Our key focus for Doptelet now is the launch in primary chronic immune thrombocytopenia (ITP) and chronic liver disease (CLD) indications throughout Europe.

Within business area **Immunology**, Kineret continues to show solid growth of 14 per cent at CER. We were pleased that we were able, within a very short timeframe, to submit anakinra in July for treatment of treatment of COVID-19 pneumonia. Gamifant sales reached SEK 168 M (132), an increase of 46 per cent at CER. The number of patients treated continued to increase in the quarter, but sales fluctuate depending on weight and the treatment period for patients. Awareness and knowledge are main drivers of sales and we continue to gain traction with our education and awareness programmes about haemophagocytic lymphohistiocytosis (HLH) in the US.

We have continued to invest in the expansion of our international footprint, as well as ongoing and upcoming launches. The rollout of Doptelet for the ITP indication in Europe is ongoing and countries have been added in the second quarter; we are also well underway in preparation for the potential launch of pegcetacoplan in PNH and the COVID-19 indication for anakinra.

As we accelerate our pipeline, step up our international launches of Doptelet and Gamifant, and prepare for the commercialisation of pegcetacoplan, we are laying the foundation for future double-digit growth and securing Sobi's long-term interests.

I am proud of the Sobi team, of how we are able to manage the ambiguities and challenges of the present and hold course to systematically strengthen our company for the future.

Solna, Sweden, 21 July 2021

Guido Oelkers, President & CEO

Financial performance

Total revenue

Total revenue for the quarter amounted to SEK 3,211 M (3,070), an increase of 5 per cent compared with the same period last year and 14 per cent at CER. Growth was mainly driven by Alprolix, Doptelet and Gamifant and the recently in-licensed products Tegsedi and Waylivra under the agreement with Akcea.

Half-year revenue was SEK 6,872 M (7,709), a decrease of 11 per cent and -2 per cent at CER.

SEK M	Q2 2021	Q2 2020	Change	Change at CER[1]	H1 2021	H1 2020	Change	Change at CER[1]	Full-year 2020
Haematology	2,125	2,037	4%	12%	4,003	4,431	-10%	-3%	8,660
Immunology	752	714	5%	17%	2,305	2,514	-8%	3%	5,415
Specialty Care	334	319	5%	14%	564	764	-26%	-20%	1,186
Total	**3,211**	**3,070**	**5%**	**14%**	**6,872**	**7,709**	**-11%**	**-2%**	**15,261**

[1]Constant exchange rates.

Gross profit

Gross profit for the quarter was SEK 2,428 M (2,381), representing a gross margin of 76 per cent (78). The margin decrease was driven by unfavourable currency effects, mandatory price reduction for Elocta in Germany, and by unfavourable product and country mix relating to Tegsedi and Waylivra sales and to sales of Doptelet to partner in China.

Half-year gross profit was SEK 5,363 M (5,979) representing a gross margin of 78 per cent (78).

Operating expenses

Sales and administrative expenses, excluding amortisation and write-downs, amounted to SEK 1,014 M (1,000) for the quarter and SEK 1,994 M (2,061) for the half year. For the quarter expenses increased by 11 per cent at CER, reflecting launch preparations for pegcetacoplan, activities related to Doptelet and haemophilia products. Expenses related to the new partner products Tegsedi and Waylivra are also reflected.

Research and development expenses amounted to SEK 484 M (345) for the quarter and to SEK 954 M (703) for the half year. The increase reflects mainly spending related to the programmes for emapalumab, pegcetacoplan and SEL-212.

Operating profit

SEK M	Q2 2021	Q2 2020	H1 2021	H1 2020	Full-year 2020
Total revenue	3,211	3,070	6,872	7,709	15,261
Cost of goods sold	-783	-689	-1,509	-1,730	-3,225
Gross profit	**2,428**	**2,381**	**5,363**	**5,979**	**12,036**
Gross margin	*76%*	*78%*	*78%*	*78%*	*79%*
Selling and administrative expenses before amortisation and write-downs	-1,014	-1,000	-1,994	-2,061	-4,099
Research and development expenses	-484	-345	-954	-703	-1,594
Total opex less amortisation and write-downs	**-1,497**	**-1,344**	**-2,949**	**-2,764**	**-5,693**
Other operating income/expenses	-9	-19	-9	-24	357
EBITA	**922**	**1,018**	**2,406**	**3,191**	**6,700**
Non-recurring items	–	–	–	–	-399
EBITA adjusted[1]	***922***	***1,018***	***2,406***	***3,191***	***6,301***
Amortisation and write-downs related to Sales and administrative expenses	-455	-477	-905	-953	-1,882
EBIT (Operating profit)	**467**	**541**	**1,500**	**2,238**	**4,818**

This is non-IFRS financial information. For an IFRS income statement, please refer to the Consolidated statement of comprehensive income.

[1]EBITA full-year 2020 excluding non-recurring items; other operating income related to the reversal of the CVR liability of SEK 399 M.

Operating profit
EBITA for the quarter was SEK 922 M (1,018), corresponding to a margin of 29 per cent (33). Half-year EBITA amounted to SEK 2,406 M (3,191), corresponding to a margin of 35 per cent (41). Amortisation of intangible assets for the quarter amounted to SEK 455 M (477) and SEK 905 M (953) for the half year. EBIT for the quarter amounted to SEK 467 M (541). EBIT for the half year amounted to SEK 1,500 M (2,238).

Net financial items
Net financial items amounted to SEK -112 M (-182) for the quarter and for the half year to SEK -227 M (-324). The improvement reflects lower debt in 2021 and negative exchange rates effects in 2020.

Tax
Income tax amounted to SEK -87 M (-75) for the quarter, corresponding to an effective tax rate of 24.5 per cent (20.9). For the half year income tax amounted to SEK -309 M (-450), corresponding to an effective tax rate of 24.3 per cent (23.5). The higher effective tax rate was mainly driven by an increased impact from higher tax jurisdictions.

Profit
Profit totalled SEK 268 M (283) for the quarter and SEK 964 M (1,465) for the half year.

Cash flow
Cash flow from operating activities before changes in working capital amounted to SEK 766 M (655) for the quarter and to SEK 1,522 M (2,435) for the half year. Changes in working capital for the quarter affected cash flow by SEK 627 M (1,287), reflecting lower sales in the first quarter 2021 compared to the first quarter 2020 due to the lower RSV season. Half year working capital affected cash flow by SEK 1,670 M (1,393).

Cash flow from investing activities was SEK -14 M (-124) for the quarter and SEK -105 M (-147) for the half year.

Cash and net debt
At the end of the quarter, cash and cash equivalents amounted to SEK 233 M (SEK 404 M at 31 Dec 2020). Sobi ended the first half of 2021 with undrawn committed credit facilities totalling SEK 5,331 M (SEK 4,320 M at 31 Dec 2020) and drawn credit facilities totalling SEK 11,507 M (SEK 14,234 M at 31 Dec 2020). Net debt at the end of the half year amounted to SEK 11,206 M (SEK 13,748 M at 31 Dec 2020). The decrease in net debt was mainly driven by operating cash flow generated in the period.

Equity
At 30 June 2021, consolidated shareholders' equity was SEK 21,174 M, compared with SEK 20,206 M at 31 Dec 2020.

Personnel
At 30 June 2021, the number of full-time equivalents was 1,537 (1,509 at 31 Dec 2020).

Parent Company
In the second quarter, net sales for the Parent Company, Swedish Orphan Biovitrum AB (publ), amounted to SEK 2,280 M (3,251), of which Group companies accounted for SEK 1,110 M (2,157). Half-year sales amounted to SEK 4,743 M (7,452) of which SEK 2,507 (3,814) referred to Group companies sales. The decrease reflects the transfer of the Synagis sales to the US subsidiary during 2020.

Profit amounted to SEK 859 M (1,537) for the quarter and to SEK 1,124 M (2,700) for the half year.

Investing activities affecting cash flow amounted to SEK 14 M (20) for the quarter and SEK 39 M (34) for the year.

Haematology

Revenue is generated from sales of the products Elocta, Alprolix and Doptelet. Revenue is also derived from manufacturing of the drug substance for ReFacto AF®/Xyntha® for Pfizer and royalty of Sanofi's sales of Eloctate® and Alprolix.

Revenue Haematology

SEK M	Q2 2021	Q2 2020	Change	Change at CER[1]	H1 2021	H1 2020	Change	Change at CER[1]	Full-year 2020
Elocta	1,005	1,040	-3%	2%	1,861	2,399	-22%	-18%	4,585
Alprolix	438	363	21%	27%	851	851	0%	6%	1,705
Royalty	320	336	-5%	11%	618	671	-8%	6%	1,301
Doptelet	230	186	24%	42%	411	251	64%	88%	587
Manufacturing	132	112	18%	18%	262	260	1%	1%	481
Total	**2,125**	**2,037**	**4%**	**12%**	**4,003**	**4,431**	**-10%**	**-3%**	**8,660**

[1]Constant exchange rates.

Revenue

Haematology revenue amounted to SEK 2,125 M (2,037) for the quarter, an increase of 4 per cent and 12 per cent at CER. Half-year revenue amounted to SEK 4,003 M (4,431), -10 per cent and -3 per cent at CER.

Elocta sales were SEK 1,005 M (1,040) for the quarter, -3 per cent and up 2 per cent at CER. Sales were driven by continued patient growth, partly offset by lower consumption per patient due to the COVID-19, mandated price reduction in Germany as communicated in Q1, and unfavourable order patterns. In Q2 2020, sales were negatively impacted by inventory de-stocking of M 154 SEK as an effect of COVID-19. Patient growth for Elocta was 3 per cent compared with the same period last year and 1 per cent compared with the previous quarter. Half-year sales amounted to SEK 1,861 M (2,399), -22 per cent and -18 per cent at CER.

Alprolix sales were SEK 438 M (363) for the quarter, an increase of 21 per cent and 27 per cent at CER. Growth reflects patient growth, favourable order patterns and de-stocking effects of M 38 SEK in Q2 2020. Patient growth for Alprolix was 16 per cent compared with the same period last year and 4 per cent compared with the previous quarter. Half-year sales amounted to SEK 851 M (851), up 6 per cent at CER.

Doptelet sales were SEK 230 M (186) for the quarter, an increase of 24 per cent and 42 per cent at CER. Growth was driven by continued launch progress in the US as well as sales to the partner in China amounting to SEK 58 M. The same quarter last year includes a milestone revenue of SEK 87 M. Half-year sales amounted to SEK 411 M (251).

Estimated royalty revenue was SEK 320 M (336) for the quarter and SEK 618 M (671) for the half year.

ReFacto manufacturing revenue totalled SEK 132 M (112) for the quarter and SEK 262 M (260) for the half-year.

Events

- The first patient was dosed in the XTEND-Kids study of efanesoctocog alfa (BIVV001) in paediatric subjects with severe haemophilia A. XTEND-Kids is designed to investigate the efficacy, safety and pharmacokinetics of efanesoctocog alfa as once-weekly prophylaxis.

Immunology

Revenue is generated from sales of the products Kineret, Synagis® and Gamifant.

Revenue Immunology

SEK M	Q2 2021	Q2 2020	Change	Change at CER[1]	H1 2021	H1 2020	Change	Change at CER[1]	Full-year 2020
Kineret	550	530	4%	14%	1,092	1,030	6%	17%	2,079
Synagis	33	52	-35%	-29%	912	1,248	-27%	-16%	2,726
Gamifant	168	132	27%	46%	301	236	27%	47%	609
Total	**752**	**714**	**5%**	**17%**	**2,305**	**2,514**	**-8%**	**3%**	**5,415**

[1]Constant exchange rates.

Revenue

Immunology revenue for the quarter amounted to SEK 752 M (714) an increase of 5 per cent and 17 per cent at CER. Half-year revenue was SEK 2,305 M (2,514), -8 per cent and up 3 per cent at CER.

Kineret sales for the quarter were SEK 550 M (530), an increase of 4 per cent and 14 per cent at CER. Kineret continued to perform well, driven by new indications, patient growth and COVID-19. Half-year sales were SEK 1,092 M (1,030) an increase of 6 per cent and 17 per cent at CER.

Synagis sales for the quarter were SEK 33 M (52). Half-year sales were SEK 912 M (1,248), highly affected by the very low RSV virology in the first quarter and stocking in Q4 2020.

Gamifant sales for the quarter amounted to SEK 168 M (132), an increase of 27 per cent and 46 per cent at CER, reflecting increased demand and continued patient growth. Half-year sales of Gamifant were SEK 301 M (236).

Events

- Sobi and the Hellenic Institute for the Study of Sepsis announced positive result from the SAVE-MORE study. The study showed that early use of anakinra reduces risk of mortality for patients with COVID-19 pneumonia, reduces ICU admission and increases likelihood of full recovery.

Specialty Care

Revenue is generated from sales of Orfadin®, Tegsedi® and other products in the Specialty Care portfolio.

Revenue Specialty Care

SEK M	Q2 2021	Q2 2020	Change	Change at CER[1]	H1 2021	H1 2020	Change	Change at CER[1]	Full-year 2020
Orfadin	125	167	-25%	-18%	222	363	-39%	-33%	665
Other Specialty Care	209	152	37%	49%	342	401	-15%	-8%	521
Total	**334**	**319**	**5%**	**14%**	**564**	**764**	**-26%**	**-20%**	**1 186**

[1]Constant exchange rates.

Revenue

Specialty Care revenue for the quarter was SEK 334 M (319), an increase of 5 per cent and 14 per cent at CER. Half-year sales were SEK 564 M (764), -26 per cent and -20 per cent at CER.

Orfadin sales for the quarter were SEK 125 M (167), -25 per cent and -18 per cent at CER, explained by generic competition and associated price erosion. Half-year sales were SEK 222 M (363), -39 per cent and -33 per cent at CER.

Q2 sales for other Specialty Care products were SEK 209 M (152), an increase of 37 per cent and 49 per cent at CER driven by the new products Tegsedi and Waylivra. Half-year sales were SEK 342 M (401), -15 per cent and -8 per cent at CER.

Events

- The license agreement with Akcea, that added Tegsedi and Waylivra to Sobi's portfolio in Europe, the Middle East, some Central European countries and Russia, was extended in Q2 to include Tegsedi in the United States.

Research and Development

Highlights within late-stage projects in the second quarter:

- Sobi and Apellis announced positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH.
- First patient was dosed in phase 3 XTEND-Kids study with efanesoctocog alfa in children with haemophilia A.
- Data was presented at the EHA (European Haematology Association) virtual congress on the use of Doptelet (avatrombopag) in chronic immune thrombocytopenia (ITP) and pegcetacoplan in paroxysmal nocturnal haemoglobinuria (PNH).

Research and Development expenses

SEK M	Q2 2021	Q2 2020	H1 2021	H1 2020	Full-year 2020
Research and development expenses	-484	-345	-954	-703	-1,594
Total revenue	3,211	3,070	6,872	7,709	15,261
Research and development expenses in relation to total revenue	**15%**	**11%**	**14%**	**9%**	**10%**

Other information

Significant events after the reporting period

In July, Kineret was submitted to EMA with a proposed indication for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia who are at risk of developing severe respiratory failure. The submission was primarily based on the investigator sponsored SAVE-MORE study. In addition, the investigator sponsored SAVE study and safety data from multiple sources support the efficacy and safety of Kineret in COVID-19 patients.

Sustainability

Sobi continues to deliver on its primary contribution to social sustainability—access to medicine—with expanded access to rare disease treatments. Responsible behaviour in operations and the supply chain is continuously promoted, and Sobi engages in dialogue with internal and external stakeholders on areas covering labour rights, ethics and responsible sourcing.

Outlook 2021—unchanged

The outlook for 2021 is expressed at January 2021 closing exchange rates. The negative currency impact on 2021 performance is expected to be 5-7 per cent on revenues and 6-8 per cent on EBITA compared with average full-year 2020 exchange rates.

Revenue for the full-year 2021 is expected to be in the range of SEK 14,000–15,000 M. At constant exchange rates this range corresponds to a revenue growth between -2.5 and 4.5 per cent.

EBITA margin is expected to be in the range of 30–35 per cent of revenue.

R&D expenses as a share of revenue are expected to grow to 13–15 per cent reflecting increased investments in SEL-212 and pegcetacoplan, and support for our late-stage programmes.

Forward-looking statements

This report includes forward-looking statements. Actual results may differ from those stated. Internal factors such as the successful management of research programmes and intellectual property rights may affect future results. There are also external conditions such as the economic climate, political changes and competing research programmes that may affect Sobi's results.

Financial calendar

Q3 2021	28 October 2021
Q4 2021	10 February 2022

This report has not been reviewed by the Company's auditors.

The Board of Directors and the CEO of Swedish Orphan Biovitrum AB (publ) provide their assurance that the interim report provides a fair and true overview of the Parent Company's and the Group's operations, financial position and results, and describes material risks and uncertainties faced by the Parent Company and the companies in the Group.

Stockholm, 21 July 2021

Håkan Björklund Chairman	Annette Clancy Board Member	Matthew Gantz Board Member
Helena Saxon Board Member	Staffan Schüberg Board Member	Filippa Stenberg Board Member
Elisabeth Svanberg Board Member	Anders Ullman Board Member	Pia Axelson Employee Representative
Erika Husing Employee Representative	Guido Oelkers CEO and President	

Financial statements – Group

Consolidated statement of comprehensive income

SEK M	Q2 2021	Q2 2020	H1 2021	H1 2020	Full-Year 2020
Total revenue[1]	3,211	3,070	6,872	7,709	15,261
Cost of goods sold	-783	-689	-1,509	-1,730	-3,225
Gross profit	**2,428**	**2,381**	**5,363**	**5,979**	**12,036**
Selling and administrative expenses[2]	-1,468	-1,477	-2,900	-3,013	-5,981
Research and development expenses	-484	-345	-954	-703	-1,594
Other operating income/expenses	-9	-19	-9	-24	357
Operating profit	**467**	**541**	**1,500**	**2,238**	**4,818**
Net financial items[3]	-112	-182	-227	-324	-601
Profit before tax	**354**	**358**	**1,273**	**1,915**	**4,217**
Income tax	-87	-75	-309	-450	-972
Profit for the period	**268**	**283**	**964**	**1,465**	**3,245**
All earnings are attributable to Parent Company shareholders					
Other comprehensive income					
Items that cannot be reclassified into profit or loss					
Remeasurements on defined-benefit plans (net of tax)	0	6	8	6	-3
Fair value of equity instruments (net of tax)	-3	–	4	–	9
Total	**-3**	**6**	**12**	**6**	**6**
Items that can be reclassified into profit or loss					
Translation differences	-72	-644	66	150	-434
Net investment hedges (net of tax)	59	78	-88	38	246
Cash flow hedges (net of tax)	28	213	-34	-28	130
Total	**15**	**-353**	**-56**	**160**	**-58**
Other comprehensive income	**12**	**-347**	**-44**	**166**	**-52**
Comprehensive income for the period	**280**	**-64**	**921**	**1,631**	**3,193**
All comprehensive income are attributable to Parent Company shareholders					
Earnings per share, SEK	0.91	0.96	3.27	4.98	11.01
Earnings per share, SEK, adjusted[4]	0.91	0.96	3.27	4.98	9.66
Earnings per share after dilution, SEK	0.90	0.95	3.26	4.94	10.90
Earnings per share after dilution, SEK, adjusted[4]	0.90	0.95	3.26	4.94	9.56
[1]See page 3 for split by business area.					
[2]Amortisation and write-downs of intangible assets included in Sales and administrative expenses.	-455	-477	-905	-953	-1,882
[3]Including financing costs.	-9	-7	-18	-14	-32

[4]Alternative Performance Measures (APMs), see page 19 for further information.

Consolidated balance sheet

SEK M	Jun 2021	Dec 2020	Jun 2020
ASSETS			
Non-current assets			
Intangible assets[1]	38,277	38,791	36,361
Tangible assets	491	534	594
Financial assets	184	179	50
Deferred tax assets	555	611	534
Total non-current assets	**39,507**	**40,115**	**37,540**
Current assets			
Inventories	3,302	3,053	2,146
Accounts receivable	2,337	3,756	2,119
Other receivables, non-interest bearing	817	955	624
Cash and cash equivalents	233	404	213
Total current assets	**6,689**	**8,168**	**5,102**
Total assets	**46,197**	**48,283**	**42,642**
EQUITY AND LIABILITIES			
Shareholders´ equity	**21,174**	**20,206**	**18,584**
Non-current liabilities			
Borrowings	9,414	10,137	12,015
Deferred tax liabilities	3,473	3,464	3,495
Lease liabilities	268	308	365
Other liabilities, non-interest bearing	3,915	3,725	2,900
Total non-current liabilities	**17,070**	**17,634**	**18,775**
Current liabilities			
Borrowings	2,025	4,015	–
Accounts payable	434	569	456
Lease liabilities	112	111	111
Other liabilities, non-interest bearing	5,381	5,748	4,715
Total current liabilities	**7,952**	**10,443**	**5,283**
Total equity and liabilities	**46,197**	**48,283**	**42,642**

[1]Including goodwill of SEK 6,006 M (SEK 5,873 at 31 Dec 2020).

Changes in equity

SEK M	Jan-Jun 2021	Full-year 2020	Jan-Jun 2020
Opening balance	**20,206**	**16,930**	**16,930**
Adjusted opening balance for post employment-benefits from prior years[1]	–	-38	-38
Share-based compensation to employees	56	114	52
Share-based compensation to employees tax effect[2]	-8	7	10
Comprehensive income for the period[3]	921	3,193	1,631
Equity at end of period	**21,174**	**20,206**	**18,584**

[1]Refers to post employment-benefits, mainly in Switzerland not previously included at Dec 2019 (net of tax).

[2]The change relates to difference between the market value of vested shares and recognised IFRS 2 cost.

[3]Whereof changes in cash flow hedges (net of tax) amounted to SEK -34 M (SEK 130 M at 31 Dec 2020) and net investment hedges (net of tax) amounted to SEK -88 M (SEK 246 M at 31 Dec 2020).

Consolidated cash flow statement

SEK M	Q2 2021	Q2 2020	H1 2021	H1 2020	Full-year 2020
Profit before tax[1]	354	358	1,273	1,915	4,217
Amortisation and depreciation	490	510	976	1,018	2,023
Other, including non-cash items	84	-36	69	105	46
Income tax paid	-162	-177	-796	-603	-918
Cash flow from operating activities before change in working capital	**766**	**655**	**1,522**	**2,435**	**5,367**
Changes in working capital	627	1,287	1,570	1,393	-442
Cash flow from operating activities	**1,393**	**1,942**	**3,092**	**3,828**	**4,926**
Investment in intangible assets[2]	-10	-110	-95	-124	-3,811
Investment in tangible assets	-6	-14	-12	-23	-41
Investment in financial assets[2]	–	–	–	–	-120
Disposal of tangible assets	2	–	2	–	8
Cash flow from investing activities	**-14**	**-124**	**-105**	**-147**	**-3,964**
Borrowings/repayments of borrowings	-1,716	-2,375	-2,879	-4,237	-1,452
Hedging arrangement for financing	-32	-32	-223	83	288
Repayment of leasing	-31	-33	-61	-59	-118
Cash flow from financing activities	**-1,778**	**-2,440**	**-3,163**	**-4,213**	**-1,282**
Change in cash and cash equivalents	**-399**	**-622**	**-176**	**-532**	**-320**
Cash and cash equivalents at the beginning of the period	633	842	404	737	737
Translation difference in cash flow and cash and cash equivalents	-1	-7	4	8	-13
Cash and cash equivalents at the end of the period	**233**	**213**	**233**	**213**	**404**

[1]As of 2021, Sobi has changed the form of presentation for the cash flow statement, see Note 1 for more information.

[2]2020 investmenst mainly refers to SEL-212 and pegcetacoplan.

Key ratios and other information

SEK M	Q2 2021	Q2 2020	H1 2021	H1 2020	Full-year 2020
Profit measures					
Gross profit	2,428	2,381	5,363	5,979	12,036
EBITDA[1]	957	1,051	2,476	3,257	6,830
EBITA[1]	922	1,018	2,406	3,191	6,700
EBITA adjusted[1,2]	922	1,018	2,406	3,191	6,301
EBIT (operating profit)	467	541	1,500	2,238	4,818
Profit/loss	268	283	964	1,465	3,245
Per share data (SEK)					
Earnings per share	0.91	0.96	3.27	4.98	11.01
Earnings per share, adjusted[2,3]	0.91	0.96	3.27	4.98	9.66
Earnings per share after dilution	0.90	0.95	3.26	4.94	10.90
Earnings per share after dilution, adjusted[2,3]	0.90	0.95	3.26	4.94	9.56
Shareholders' equity per share[1]	69.7	62.0	69.7	62.0	66.5
Shareholders' equity per share after dilution[1]	69.5	61.5	69.5	61.5	65.9
Other information					
Gross margin[1]	76%	78%	78%	78%	79%
EBITA margin[1]	29%	33%	35%	41%	44%
EBITA margin adjusted[1,2]	29%	33%	35%	41%	41%
Equity ratio[1]	46%	44%	46%	44%	42%
Net debt[1]	11,206	11,802	11,206	11,802	13,748
Number of ordinary shares[4]	303,815,511	299,977,839	303,815,511	299,977,839	303,815,511
Number of ordinary shares (in treasury)	8,670,882	5,081,000	8,670,882	5,081,000	8,918,672
Number of ordinary shares (excluding shares in treasury)	295,144,629	294,896,839	295,144,629	294,896,839	294,896,839
Number of ordinary shares after dilution	304,828,251	302,233,434	304,828,251	302,233,434	306,797,549
Average number of ordinary shares (excluding shares in treasury)	295,007,237	294,744,579	294,953,465	294,416,809	294,658,136
Average number of ordinary shares after dilution (excluding shares in treasury)	296,019,976	297,000,174	295,966,205	296,672,404	297,640,174

[1]Alternative performance measures (APMs), see page 19 for further information.

[2]EBITA full-year 2020 excluding non-recurring items; other operating income related to the reversal of the CVR liability of SEK 399 M.

[3]EPS full-year 2020 excluding the reversal of the CVR liability SEK 399 M.

[4]The increase in the number of shares results from an issue of 3,837,672 shares issued for the purpose of ensuring fulfilment of commitments under incentive programmes.

Financial statements – Parent Company

Income statement

SEK M	Q2 2021	Q2 2020	H1 2021	H1 2020	Full-year 2020
Total revenue	2,280	3,251	4,743	7,452	13,968
Cost of goods sold	-632	-739	-1,249	-1,745	-3,134
Gross profit	**1,648**	**2,512**	**3,493**	**5,707**	**10,834**
Selling and administrative expenses[1]	-556	-652	-1,614	-2,100	-4,174
Research and development expenses	-278	-198	-589	-408	-923
Other operating income/expenses	70	17	128	7	96
Operating profit	**883**	**1,679**	**1,417**	**3,206**	**5,833**
Net financial items	72	57	-118	2	194
Profit after financial items	**955**	**1,736**	**1,299**	**3,208**	**6,027**
Appropriations	–	–	–	–	-1,690
Profit before tax	**955**	**1,736**	**1,299**	**3,208**	**4,337**
Income tax expenses	-95	-199	-176	-508	-931
Profit for the period	**859**	**1,537**	**1,124**	**2,700**	**3,406**
[1]Amortisation and write-downs of intangible assets included in Sales and administrative expenses.	-87	-80	-170	-160	-328

Statement of comprehensive income

SEK M	Q2 2021	Q2 2020	H1 2021	H1 2020	Full-year 2020
Profit for the period	859	1,537	1,124	2,700	3,406
Items that cannot be reclassified into profit or loss					
Fair value of equity instruments (net of tax)	-3	–	4	–	9
Items that can be reclassified into profit or loss					
Cash flow hedges (net of tax)	28	208	-34	-33	130
Comprehensive income for the period	**885**	**1,744**	**1,094**	**2,667**	**3,545**

Balance sheet

SEK M	Jun 2021	Dec 2020	Jun 2020
ASSETS			
Non-current assets			
Intangible assets	10,055	10,205	5,437
Tangible assets	57	64	72
Financial assets	23,733	23,164	25,274
Deferred tax assets	20	24	24
Total non-current assets	**33,865**	**33,457**	**30,807**
Current assets			
Inventories	2,564	2,527	1,738
Accounts receivable	857	731	716
Receivables Group companies	2,406	3,947	2,051
Other receivables, non-interest bearing	693	835	489
Cash and cash equivalents	70	240	85
Total current assets	**6,590**	**8,280**	**5,078**
Total assets	**40,455**	**41,737**	**35,885**
EQUITY AND LIABILITIES			
Shareholders´ equity	**18,341**	**17,200**	**16,263**
Untaxed reserves	3,091	3,091	2,984
Non-current liabilities			
Borrowings	9,414	10,137	12,015
Liabilities Group companies	–	157	175
Other liabilities, non-interest bearing	2,693	2,557	1,387
Total non-current liabilities	**12,107**	**12,851**	**13,577**
Current liabilities			
Borrowings	2,025	4,015	–
Accounts payable	235	398	296
Liabilities Group companies	2,814	1,674	473
Other liabilities, non-interest bearing	1,841	2,508	2,292
Total current liabilities	**6,915**	**8,595**	**3,061**
Total equity and liabilities	**40,455**	**41,737**	**35,885**

Change in shareholders' equity

SEK M	Jan-Jun 2021	Full-year 2020	Jan-Jun 2020
Opening balance	**17,200**	**13,534**	**13,534**
Share-based compensation to employees	56	114	52
Share-based compensation to employees tax effect	-8	7	10
Comprehensive income for the period[1]	1,094	3,545	2,667
Equity at end of period	**18,341**	**17,200**	**16,263**

[1]Whereof changes in cash flow hedges (net of tax) amounted to SEK -34 M (SEK 130 M at 31 Dec 2020).

Notes

Note 1 Accounting policies and measurement bases and other information

Accounting policies

This interim report has been prepared in accordance with IAS 34 and the Swedish Annual Accounts Act. The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and the International Financial Reporting Interpretations Committee (IFRIC) as adopted by the EU. The Parent Company applies the Annual Accounts Act and the Swedish Financial Reporting Board's Recommendation RFR 2 Accounting for Legal Entities. The accounting policies apply with those described in the 2020 Annual and Sustainability Report. IASB has published amendments of standards that are effective as of 1 January 2021 or later. The standards have not had any material impact on the consolidated financial statements.

More detailed information about the Group's accounting policies and measurement bases can be found in the 2020 Annual and Sustainability Report, available at www.sobi.com.

Cash flow statement

As of 2021, Sobi has changed the form of presentation for the cash flow statement and reclassified hedging arrangements for financing from cash flow from operating activities to cash flow from financing activities. Comparative figures for 2020 have been recalculated, whereby the cash flow from operating activities for the period April-June 2020 has been adjusted from SEK 1,911 M to SEK 1,942 M, period January-June 2020 has been adjusted from SEK 3,912 M to SEK 3,828 M and for the full-year 2020 from SEK 5,214 M to SEK 4,926 M. Cash-flow from financing activities has been adjusted for the corresponding periods from SEK -2,409 M to SEK -2,440 M, SEK -4,297 M to SEK -4,213 M and from SEK -1,570 M to -1,282, respectively.

Risks and uncertainties

Sobi is exposed to a number of risks in its operations. Effective risk management aligns Sobi's business opportunities and profit with shareholders' and other stakeholders' demands for stable, long-term value growth and control. Key risk areas are summarised below:

- Pandemics and other external events
- Strategic and operational risk
- Commercialisation and business environment
- Financial and reporting risk
- Compliance risk

More information about risk exposure and risk management is included in Sobi's 2020 Annual and Sustainability Report.

Note 2 Segment reporting

SEK M

Q2 2021	Haematology	Immunology	Specialty Care	Group - other	Total
Revenue	2,125	752	334	–	3,211
EBITA[1]	992	-69	102	-102	922
Adjusted EBITA[1,2]	992	-69	102	-102	922
Amortisation	-151	-251	-40	-12	-455
EBIT (Operating profit)	840	-321	62	-115	467

Q2 2020	Haematology	Immunology	Specialty Care	Group - other	Total
Revenue	2,037	714	319	–	3,070
EBITA[1]	1,046	-90	184	-122	1,018
EBITA adjusted [1,2]	1,046	-90	184	-122	1,018
Amortisation	-166	-254	-46	-11	-477
EBIT (Operating profit)	880	-344	138	-133	541

H1 2021	Haematology	Immunology	Specialty Care	Group - other	Total
Revenue	4,003	2,305	564	–	6,872
EBITA[1]	1,813	664	174	-245	2,406
EBITA adjusted [1,2]	1,813	664	174	-245	2,406
Amortisation	-302	-502	-78	-23	-905
EBIT (Operating profit)	1,511	161	96	-268	1,500

H1 2020	Haematology	Immunology	Specialty Care	Group - other	Total
Revenue	4,431	2,514	764	–	7,709
EBITA[1]	2,243	775	424	-251	3,191
EBITA adjusted [1,2]	2,243	775	424	-251	3,191
Amortisation	-332	-508	-92	-22	-953
EBIT (operating profit)	1,911	267	332	-272	2,238

Full-year 2020	Haematology	Immunology	Specialty Care	Group - other	Total
Revenue	8,660	5,415	1,187	–	15,261
EBITA[1]	4,377	1,902	564	-143	6,700
EBITA adjusted [1,2]	3,978	1,902	564	-142	6,301
Amortisation	-652	-1,009	-179	-42	-1,882
EBIT (Operating profit)	3,725	893	385	-185	4,818

There are no intersegment transactions.

[1]Alternative Performance Measures (APMs), see page 19 for further information.

[2]EBITA 2020 excluding non-recurring items; other operating income related to the reversal of the CVR liability of SEK 399 M.

[3]The category Group-other mainly refers to costs for central functions such as finance, legal, communication, human resources and other items that can not be allocated by segment.

Note 3 Fair value of financial instruments

The following table shows financial instruments measured at fair value, based on their classification in the fair value hierarchy. Sobi's financial instruments at fair value at the end of the quarter consist of equity instruments, derivatives held for trading and endowment policies.

Equity instruments are categorised within level 1 and consist of the Group's holding of quoted shares in Selecta Biosciences, Inc. Fair value measurement is based on quoted prices in active markets. Derivatives held for trading are categorised within level 2 and consist of currency derivatives forward contracts. Fair value measurement is based on published forward prices. Endowment insurances are categorised within level 3. No transfers have been made between the levels during the period.

At 30 June 2021, all other financial instruments on the balance sheet had reported values that are in all material aspects equivalent to fair value.

The contingent consideration in Q2 2020 refers to the CVR which was reversed during the fourth quarter in 2020. See page 20 for more information.

SEK M

Q2 2021	Level 1	Level 2	Level 3	Total
Financial assets and liabilities measured at fair value through profit or loss				
Derivatives held for trading	–	-1	–	**-1**
Endowment policies	–	–	44	**44**
Financial assets measured at fair value through other comprehensive income				
Equity instruments	136	–	–	**136**
Total	**136**	**-1**	**44**	**179**

Q2 2020	Level 1	Level 2	Level 3	Total
Financial assets and liabilities measured at fair value through profit or loss				
Derivatives held for trading	–	-32	–	**-32**
Endowment policies	–	–	47	**47**
Contingent considerations	–	–	-400	**-400**
Total	**–**	**-32**	**-353**	**-385**

Full-year 2020	Level 1	Level 2	Level 3	Total
Financial assets and liabilities measured at fair value through profit or loss				
Derivatives held for trading	–	-151	–	**-151**
Endowment policies	–	–	44	**44**
Financial assets measured at fair value through other comprehensive income				
Equity instruments	131	–	–	**131**
Total	**131**	**-151**	**44**	**24**

Alternative performance measures—Financial measures not defined according to IFRS

Sobi uses certain financial measures (alternative performance measures, APM) in the interim report that are not defined according to IFRS. The company considers these measures to provide valuable supplementary information for investors and company management, as they enable an assessment and benchmarking of the company's reporting. Since not all companies calculate financial measures in the same way, these are not always comparable to measures used by other companies. These financial measures should not, therefore, be regarded as substitutes for measures defined according to IFRS. The following metrics are not defined according to IFRS:

SEK M unless otherwise stated

	Q2 2021	Q2 2020	H1 2021	H1 2020	Full-year 2020
Total revenue	3,211	3,070	6,872	7,709	15,261
Total cost of goods sold	-783	-689	-1,509	-1,730	-3,225
Gross profit	**2,428**	**2,381**	**5,363**	**5,979**	**12,036**
Gross margin	**76%**	**78%**	**78%**	**78%**	**79%**
EBIT (operating profit)[1]	467	541	1,500	2,238	4,818
Plus amortisation and write-downs of intangible assets	455	477	905	953	1,882
EBITA[1]	**922**	**1,018**	**2,406**	**3,191**	**6,700**
Plus depreciations and write-downs of tangible assets	36	33	70	66	130
EBITDA	**957**	**1,051**	**2,476**	**3,257**	**6,830**
EBITA margin	**29%**	**33%**	**35%**	**41%**	**44%**
Non-recurring items	–	–	–	–	-399
EBITA adjusted	**922**	**1,018**	**2,406**	**3,191**	**6,301**
EBITA margin adjusted	**29%**	**33%**	**35%**	**41%**	**41%**
Profit for the period	268	283	964	1,465	3,245
Non-recurring items[2]	–	–	–	–	-399
Profit for the period, adjusted	268	283	964	1,465	2,846
Average number of ordinary shares (excluding shares in treasury)	295,007,237	294,744,579	294,953,465	294,416,809	294,658,136
Average number of ordinary shares after dilution (excluding shares in treasury)	296,019,976	297,000,174	295,966,205	296,672,404	297,640,174
EPS, SEK adjusted	**0.91**	**0.96**	**3.27**	**4.98**	**9.66**
EPS after dilution, SEK adjusted	**0.90**	**0.95**	**3.26**	**4.94**	**9.56**
Borrowings	11,439	12,015	11,439	12,015	14,152
Cash and cash equivalents	233	213	233	213	404
Net debt	**11,206**	**11,802**	**11,206**	**11,802**	**13,748**
Shareholders' equity	21,174	18,584	21,174	18,584	20,206
Total assets	46,197	42,642	46,197	42,642	48,283
Equity ratio	**46%**	**44%**	**46%**	**44%**	**42%**
Number of ordinary shares	303,815,511	299,977,839	303,815,511	299,977,839	303,815,511
Number of ordinary shares after dilution	304,828,251	302,233,434	304,828,251	302,233,434	306,797,549
Equity per share, SEK	**69.7**	**62.0**	**69.7**	**62.0**	**66.5**
Equity per share after dilution, SEK	**69.5**	**61.5**	**69.5**	**61.5**	**65.9**

[1]For EBIT and EBITA per segment see Note 2.

[2]Relates to the reversal of the CVR liability of SEK 399 M in 2020, see page 20 for more information.

Definitions—financial terms

CER	Constant exchange rates
CVR	Following the completion of Sobi's acquisition of Dova Pharmaceuticals, Inc. (Dova) on 12 November 2019, Dova shareholders were provided one non-transferrable Contingent Value Right (CVR) to an additional USD 1.50 per share to be paid upon approval of Doptelet for use in chemotherapy-induced thrombocytopenia (CIT) by the FDA. On 9 October 2020, Sobi announced topline results for phase 3 CIT study of avatrombopag. The primary endpoints were not met and Sobi estimates that the conditions of the CVR will not be met. Consequently, the corresponding liability on the balance sheet was reversed, positively impacting other operating income by SEK 399 M.
Earnings per share	The portion of a company's profit allocated to each outstanding share of common stock
EBIT (Operating profit)	Earnings before interest and tax
EBITA	Earnings before interest, tax and amortisation
EBITA margin, %	EBITA as a percentage of total revenue
EBITA adjusted	EBITA less non-recurring items
EBITA margin adjusted, %	EBITA adjusted as a percentage of total revenue
EBITDA	Earnings before interest, tax, depreciation, amortisation and write-downs
EPS, adjusted	Profit for the period, adjusted, divided by average number of ordinary shares
EPS after dilution, adjusted	Profit for the period, adjusted, divided by average number of ordinary shares after dilution
Equity ratio	Shareholders' equity as a proportion of total assets
Equity per share	Equity divided by the number of ordinary shares
Equity per share after dilution	Equity divided by the number of ordinary shares after dilution
Full-time equivalents	Unit that indicates the workload of an employed person in a way that makes workloads comparable
Gross profit	Total revenue less cost of goods sold
Gross margin	Gross profit as a percentage of total revenue
IFRS	International Financial Reporting Standards
Net debt	Borrowings less Cash and cash equivalents
Non-recurring items	Refers to items that have no clear connection with the ordinary operations and are of such a type that it cannot be expected to occur often or regularly and that it is an item of significant value. This may, for example, refer to capital gains/losses from divestments, restructuring initiatives, impairments and other unusual one-time income and expenses.

Glossary

Alprolix (eftrenonacog alfa)	A recombinant, extended half-life (EHL) clotting factor IX therapy approved in the EU, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland, as well as in Australia, Brazil, Canada, Japan, New Zealand, the United States and other countries, for the treatment of haemophilia B.
BIVV001, efanesoctocog alfa	A novel, investigational factor VIII therapy designed to extend protection from bleeds with prophylactic dosing of once weekly or longer intervals for people with haemophilia A. Builds on the Fc fusion technology by adding a region of von Willebrand factor and XTEN polypeptides to potentially extend its time in circulation.
Chronic immune thrombocytopenia (ITP)	A rare autoimmune bleeding disorder characterised by a low number of platelets, affecting approximately 60,000 adults in the United States.
Chronic liver disease (CLD)	Liver disease becomes chronic when it has been present for more than 6-12 months without signs of resolution. Chronic liver disease can be inherited (genetic) or caused by a variety of factors such as viruses, auto-immunity, obesity and alcohol use.
COVID-19	The infectious disease caused by a coronavirus discovered in 2019, declared a pandemic by WHO.
Doptelet (avatrombopag)	A second-generation small-molecule thrombopoietin receptor (TPO) agonist used in the treatment of thrombocytopenia by increasing platelet count.
Elocta (efmoroctocog alfa)	A recombinant, EHL clotting factor VIII therapy approved in the EU, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland for the treatment of haemophilia A. It is also approved in Australia, Brazil, Canada, Japan, New Zealand, the United States and other countries, where it is known as ELOCTATE.
EMA	European Medicines Agency.
FDA	The US Food & Drug Administration.
Gamifant (emapalumab)	An anti-interferon-gamma (IFN-γ) monoclonal antibody (mAb), approved by the FDA for the treatment of primary haemophagocytic lymphohistiocytosis (pHLH), a life-threatening syndrome of immune activation.
Gout	An autoinflammatory disease that causes intensely painful flares and debilitating inflammatory arthritis due to deposition of pro-inflammatory monosodium urate (MSU) crystals in synovial fluid and other tissues.
Haemophagocytic lymphohistiocytosis (HLH)	A rare and life-threatening syndrome of extreme immune activation. The primary form of the disease (pHLH, inherited) mainly occurs in infants and young children while the secondary form of the disease (sHLH, acquired) is acquired from or associated with infection, autoimmune diseases or malignancy.
Haemophilia	A rare, genetic disorder in which the ability of a person's blood to clot is impaired. Haemophilia A occurs in about one in 5,000 male births annually, and haemophilia B occurs in about one in 25,000 male births annually. Both occur more rarely in females. People with haemophilia can experience bleeding episodes that may cause pain, limited mobility, irreversible joint damage and life-threatening haemorrhages.
Kineret (anakinra)	A recombinant protein drug that blocks the biological activity of interleukin-1 α and β (IL-1α and IL -1β) by binding to IL-1 type 1 receptors (IL-R 1), expressed in a variety of tissues and organs, thereby blocking the IL-1 signalling. IL-1 is a key mediator of inflammation and a significant contributor to autoinflammatory diseases.
Orfadin (nitisinone)	A drug used to treat hereditary tyrosinaemia type 1 (HT-1). It blocks the breakdown of tyrosine, thereby reducing the amount of toxic tyrosine by-products in the body. Patients must maintain a special diet in combination with Orfadin treatment as tyrosine is not adequately broken down. Orfadin was approved in the EU in October 2020 for the treatment of adult patients with alkaptonuria (AKU).

Paroxysmal nocturnal haemoglobinuria (PNH)	A rare, chronic, life-threatening blood disorder characterised by the destruction of oxygen-carrying red blood cells through extravascular and intravascular haemolysis. Persistently low haemoglobin can result debilitating symptoms such as severe fatigue, haemoglobinuria, and difficulty breathing (dyspnoea), and the need for frequent transfusions.
Pegcetacoplan	An investigational, targeted C3 therapy designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b.
RSV	Respiratory syncytial virus. A common virus and the most common cause of lower respiratory tract infections (LRTI) in young children.
SEL-212	SEL-212 is a novel combination product candidate designed to sustain control of serum uric acid levels in patients with chronic refractory gout. SEL-212 consists of pegadricase, co-administered with ImmTOR, designed to mitigate the formation of anti-drug antibodies.
Synagis (palivizumab)	Indicated for the prevention of serious lower respiratory tract infection (LRTI) caused by RSV in infants and young children at high risk of RSV disease. RSV is the most prevalent cause of LRTI among infants and young children. Synagis is a RSV F protein inhibitor monoclonal antibody that acts as a prophylaxis against serious RSV disease.
Tegsedi (inotersen)	Tegsedi (inotersen) is a self-administered subcutaneous treatment for the polyneuropathy of hATTR amyloidosis in adults.
Waylivra (volanesorsen)	Waylivra (volanesorsen) is a treatment for genetically confirmed familial chylomicronaemia syndrome (FCS).

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and Asia. In 2020, Sobi's revenue amounted to SEK 15.3 billion.

Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm.

You can find more information about Sobi at sobi.com

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm, Sweden | Street address: Tomtebodavägen 23 A
Telephone: +46 8-697 20 00 | Fax: +46 8-697 23 30
www.sobi.com